Linagliptin/Metformin Sandoz (Metformin Hydrochloride, Linagliptin)

Linagliptin selectively inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4). By blocking DPP‑4, it prevents the rapid degradation of incretin hormones such as GLP‑1, which enhances glucose‑dependent insulin secretion and reduces glucagon release, leading to lower post‑prandial blood glucose levels.

Metformin primarily reduces hepatic glucose production by inhibiting gluconeogenesis. It also increases peripheral insulin sensitivity, enhancing glucose uptake in muscle and adipose tissue. These actions together lower fasting and post‑prandial blood glucose without stimulating insulin release.

The specific dose of Linagliptin/Metformin Sandoz is determined by the prescribing healthcare professional based on individual patient factors such as renal function, glycemic targets, and concomitant therapies. Patients should follow the dosage instructions provided by their prescriber and pharmacist.

Safety data for Linagliptin/Metformin Sandoz in pregnancy are limited, and the product is generally not recommended unless the potential benefit outweighs the risk. Metformin has been used in pregnancy for certain indications, but linagliptin is usually avoided. Breastfeeding mothers should consult their physician before use.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with separate metformin or other DPP‑4 inhibitors, the fixed‑dose combination offers convenience and may improve adherence by reducing pill burden. It provides the complementary mechanisms of both agents, often achieving better glycemic control than metformin alone, while having a safety profile similar to the individual components.

Linagliptin/Metformin Sandoz tablets should be stored at ambient temperature, below 25 °C. Keep them in the original blister pack or container, protect from moisture and direct sunlight, and keep out of reach of children.

The tablets are taken orally, usually with food to reduce gastrointestinal discomfort. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed by a healthcare professional.

Patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to either component, or a history of lactic acidosis should avoid this medication. It is also contraindicated in individuals with acute or chronic metabolic acidosis, including diabetic ketoacidosis.